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Abstract: Eosinophils are abundantly present in most phenotypes of asthma and they 
contribute to the maintenance and exacerbations of the disease. Regulators of eosinophil 
longevity play critical roles in determining whether eosinophils accumulate into the 
airways of asthmatics. Several cytokines enhance eosinophil survival promoting eosinophilic 
airway inflammation while for example glucocorticoids, the most important anti-inflammatory 
drugs used to treat asthma, promote the intrinsic pathway of eosinophil apoptosis and 
by this mechanism contribute to the resolution of eosinophilic airway inflammation. 
Mitochondria seem to play central roles in both intrinsic mitochondrion-centered and 
extrinsic receptor-mediated pathways of apoptosis in eosinophils. Mitochondria may also 
be important for survival signalling. In addition to glucocorticoids, another important agent 
that regulates human eosinophil longevity via mitochondrial route is nitric oxide, which is 
present in increased amounts in the airways of asthmatics. Nitric oxide seems to be able to 
trigger both survival and apoptosis in eosinophils. This review discusses the current evidence 
of the mechanisms of induced eosinophil apoptosis and survival focusing on the role of 
mitochondria and clinically relevant stimulants, such as glucocorticoids and nitric oxide. 
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Eosinophils are cells of the innate immune system involved in the pathogenesis of allergic, 
gastrointestinal and hypereosinophilic disorders, in anti-parasitic defence and in tumor  
immunity [1–5]. Eosinophils account only for approximately 3% of blood leukocytes in healthy 
individuals but their number is elevated in subjects with eosinophilic conditions such as allergic 
asthma. However, shortages of cells often hamper studies on eosinophils. In asthmatic airways, 
eosinophils are driven into an activated state e.g., by pro-inflammatory cytokines such as IL-5. When 
activated, they release toxic and pro-inflammatory mediators able to induce bronchoconstriction, 
mucus hypersecretion, and damage to airway epithelium as well as contribute to T helper 2 cell 
polarization and airway thickening [6–8]. Recent data from clinical studies with anti-IL-5 antibody and 
eosinophil-deficient mice suggest that eosinophils are important for asthma exacerbations and airway 
remodelling. Anti-IL-5 treatment led to decreased exacerbation rate in patients with severe 
eosinophilic asthma and these patients were able to reduce their glucocorticoid dose in response to 
anti-IL-5 treatment [9,10]. Thereby, eosinophils are important for maintenance and exacerbations of 
asthma [11].  
In healthy individuals eosinophils are short-living cells. In in vitro conditions, blood eosinophils 
undergo spontaneous apoptosis in a few days but in a physiological situation they tend to migrate  
and accumulate into liver and spleen, where they are likely to live longer than a few days [12–15]. 
Apoptosis of eosinophils can be delayed or accelerated by various agents [14,15]. Eosinophil longevity 
may be enhanced up to 1–2 weeks by pro-inflammatory cytokines such as IL-5, IL-3 and GM-CSF 
present in inflamed airways [16]. Indeed, blood and tissue eosinophils from patients with asthma have 
been shown to live longer when compared to eosinophils from healthy individuals [17,18]. Eosinophil 
removal from the airways is beneficial to reduce eosinophilic inflammation and alleviate symptoms of 
asthma [19]. Apoptosis is a non-inflammatory way of cell death comprising a beneficial means for  
cell removal. Membrane integrity is retained throughout the process and the harmful cell content 
maintained inside the cell. The immunological silence of apoptosis is ensured by formation of smaller 
apoptotic bodies that are rapidly ingested by phagocytes. Apoptosis may be executed via two different 
main routes, extrinsic (receptor-mediated) or intrinsic (mitochondrion-centered) pathway [20]. 
Extrinsic pathway is activated e.g., by ligation of the death receptor Fas/CD95. This leads to formation 
of a multiprotein complex called death-inducing signalling complex (DISC) that regulates activation of 
initiator caspase-8. Initiator caspase-8 may either directly activate effector caspases that execute 
apoptosis or cleave BH3-interacting-domain death agonist (Bid) resulting in activation of an additional 
mitochondrial loop. Intrinsic pathway can be initiated by several intracellular stress conditions such as 
DNA damage, oxidative stress and cytosolic Ca2+ overload. Members of the Bcl-2 family are critical in 
monitoring intracellular damage and aim to mediate activation of pore-forming Bax and the following 
mitochondrial membrane permeabilization (MMP), a central event in apoptosis [20,21]. Mitochondrial 
membrane permeabilization can also be mediated via mitochondrial permeability transition  
(mPT) [21,22]. MMP results in loss of mitochondrial membrane potential (∆Ψm), halted mitochondrial 
ATP synthesis and release of pro-apoptotic proteins such as cytochrome c to the cytosol. Cytochrome c 
stimulates formation of the apoptosome, a platform that activates initiator caspase-9 [20,21]. Initiator 
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caspase 9 activates effector caspases 3, 6 and 7 resulting in degradation of cellular components  
and apoptosis.  
Eosinophil apoptosis can be accelerated by physiological factors such as Fas activation [23]. Fas 
ligand is a significant pro-apoptotic agent for eosinophils in vivo because its neutralization enhanced 
airway eosinophilia in a mouse model of allergic asthma [24]. NO is produced in high amounts in the 
lungs of asthmatics and has been shown to regulate eosinophil apoptosis in a complex manner. NO has 
shown both anti- and pro-apoptotic effects on eosinophils [25–27] and both enhancing and reducing 
properties regarding lung eosinophilia [28–30]. Thereby, the net effect in response to NO can be 
different in different pathophysiological situations and is not known at the moment. Also many  
anti-asthmatic agents such as glucocorticoids, theophylline and cysteinyl leukotriene receptor 
antagonists enhance eosinophil apoptosis in the absence and presence of eosinophil  
survival-prolonging cytokines [31–36] and the pro-apoptotic effects of these drugs may contribute to 
their clinical efficacy [37–42]. Anti-inflammatory glucocorticoid medication is the corner stone in the 
treatment of asthma and understanding its actions is of critical importance. Glucocorticoids modulate 
longevity of many immune cell types and the sensitivity to glucocorticoid-induced cell death  
depends on the cell type. For example, CD4+ T cells but not CD8+ T cells are sensitive to 
glucocorticoid-induced apoptosis [43–45]. In contrast, glucocorticoids inhibited neutrophil  
apoptosis [31,46–48], even though not in an environment with severe hypoxia [49]. In eosinophils, 
glucocorticoids accelerate apoptosis [31–33].  
Understanding the signalling related to eosinophil survival and apoptosis is extremely important for 
understanding the pathogenesis of eosinophilic inflammation and for the development of novel drugs 
to treat diseases associated with eosinophilia. Studies using primary human eosinophils are hampered 
by several issues. Low numbers of cells available for the studies restricts carrying out experiments 
with long-time series and different treatments. Additionally, the short lifespan of eosinophils excludes 
use of most modern molecular biology methods such as transfection and RNA interference. Because of 
the restrictions, knowledge of primary human eosinophil functions is based mainly on the use of 
pharmacological inhibitors and methods available for direct measurements of cellular functions and 
intracellular mediators. 
In eosinophils, mitochondria play a central role in apoptosis and survival [50]. Mitochondrial events 
have been shown to be critical for spontaneous, glucocorticoid-, nitric oxide- and anti-Fas-induced 
apoptosis of eosinophils [51–54] and thereby mediate both extrinsic and intrinsic forms of eosinophil 
apoptosis. Mitochondria are forums where pro- and anti-apoptotic signals merge and the fate of the cell 
is determined. Because of the evident importance of this cell organ for eosinophil survival and death, 
this review concentrates on discussing the mechanisms of eosinophil apoptosis and survival focusing 
on the role of mitochondria and the clinically relevant pro-apoptotic stimulant glucocorticoid.  
2. Mitochondria and Bcl-2 Family Members 
In most cells, mitochondria function as “energy factories” producing ATP via function of the 
electron transport chain maintaining mitochondrial membrane potential (∆Ψm). Eosinophils have been 
suggested to contain only a low number of mitochondria, 24–36 per cells [50] but this result needs to 
be confirmed by current techniques. It has also been reported that eosinophils maintain mitochondrial 
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membrane potential rather by hydrolysis of ATP than via respiratory chain [50], even though evidence 
also exists of functional respiratory chains in eosinophils [55]. It is clear that eosinophil mitochondria 
are able to release cytochrome c from the intermembrane space and by this mechanism activate 
caspases and induce apoptosis [50].  
2.1. Bcl-2 Members and Pore-Forming Activity of Bax and Bid 
Members of the Bcl-2 family are critical in monitoring intracellular damage and the balance 
between anti-apoptotic and pro-apoptotic Bcl-2 members (ratio of pro-apoptotic Bax to anti-apoptotic 
Bcl-2) determines the susceptibility of cells to apoptosis. Short-living granulocytes have high ratios of 
Bax/Bcl-2 while the corresponding ratios in monocytes and lymphocytes are relatively low. This ratio 
determined the susceptibility of leukocytes to anti-Fas-induced apoptosis, granulocytes being the most 
susceptible and lymphocytes the least susceptible [56]. Eosinophils express high levels of  
pro-apoptotic Bid and Bax, which are proteins capable to oligomerize and form pores to the 
mitochondrial outer membrane [53,54,57,58]. Bid is processed during spontaneous apoptosis and in 
enhanced manner during glucocorticoid- and anti-Fas-induced apoptosis but it is the most critical 
mediator for Fas-induced apoptosis [53,54]. Also Bax was demonstrated to spontaneously translocate 
into mitochondria in untreated eosinophils and in an accelerated manner in response to glucocorticoid 
treatment [51,52]. Peptidyl-prolyl isomerase Pin1 may be the key regulator of Bax translocation. Bax 
translocation into mitochondria was prevented by GM-CSF, which activated ERK1/2 to phosphorylate 
the threonine residue of Bax. This phosphorylation enabled interaction of Pin1 with Bax preventing its 
mitochondrial targeting [58]. Pin1 was also shown to be a key regulator of apoptosis induced by  
anti-Fas via the Fas-associated death domain (FADD) in activated eosinophils. In the presence of  
survival-prolonging IL-5, Pin1 quenched phosphorylation of FADD at Ser194 and prevented  
apoptosis [59]. These mechanisms may be highly important in determining whether allergic 
inflammation is continued by IL-5/GM-CSF or diminished by Fas receptor signalling.  
Anti-apoptotic Mcl-1 has been found in eosinophils and was degraded during spontaneous 
apoptosis and in an accelerated manner during apoptosis induced by glucocorticoids or by an inhibitor 
of cyclin-dependent kinase [57,60–63]. In HeLa cells, Mcl-1 was demonstrated to inhibit Bax 
downstream to its mitochondrial translocation. Mcl-1 prevented formation of Bax oligomers at 
mitochondria, required for pore formation, but this inhibition required no direct interaction [64]. 
Thereby, degradation of Mcl-1 in apoptotic eosinophils probably enables pore-forming activity of  
Bax and mitochondrial outer membrane permeabilization. The mechanism of Mcl-1 degradation 
accelerated by glucocorticoids remains unclear but may for example involve transcription of proteins 
involved in the degradation [63]. In neutrophils, glucocorticoids, in contrast to eosinophils, induced 
Mcl-1 expression, which may play an important role in the mechanism of prolongation of neutrophil 
survival [65]. Contradictions exist concerning the expression of anti-apoptotic Bcl-2 in eosinophils; 
expression seems to depend on the origin of the eosinophils [39,57,60,66].  
2.2. Mitochondrial Permeability Transition 
Mitochondrial permeability transition (mPT) is one mechanism for the mitochondrial membrane 
permeabilization. During mPT, permeability of the inner mitochondrial membrane is increased for 
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solutes and molecules up to 1.5 kDa. A channel sensitive to Ca2+, oxidants and pro-apoptotic Bcl-2 
family members is responsible for this phenomenon [21,22]. Mitochondrial permeability transition 
results in mitochondrial matrix swelling, most likely due to the influx of ions that are accompanied by 
water. The mitochondrial outer membrane is ruptured due to matrix swelling and apoptosis-inducing 
proteins are released to the cytosol [67]. The mPT channel is thought to be a multiprotein complex but 
its molecular structure is still unknown. Glucocorticoids and nitric oxide induced apoptosis in 
eosinophils that was mediated by mPT [68,69]. However, mPT had no critical role in mediating 
spontaneous or anti-Fas-induced apoptosis [23]. What defines the mechanism of mitochondrial 
membrane permeabilization in response to different pro-apoptotic stimulants in eosinophils remains 
unclear. Oxidants are generally important mediators of eosinophil apoptosis and known inducers of 
mPT but do not, however, always mediate mPT. It seems that ROS have several mechanisms to 
mediate apoptosis, one of which is stimulation of mPT. For example, Bid has been shown to engage a 
ROS-dependent but mPT-independent mechanism for mitochondrial membrane permeabilization and 
cytochrome c release [70].  
Mitochondrial permeability transition may function in two different modes. In addition to the 
irreversible sustained opening of the mPT channel occurring during cell death, the channel may also 
fluctuate between open and closed states (flicker) [71,72]. In NO-treated eosinophils, early flickering 
mPT preceded permanent mPT and mPT-dependent eosinophil apoptosis [68]. The early flickering 
mPT was not necessary for apoptosis to proceed and may actually represent a cell survival  
mechanism [73,74]. It has been demonstrated that flickering mPT may act as a mechanism to release 
ROS or calcium [75–77] and by these mechanisms, flickering mPT may participate in cell signalling. 
For example, in NO-treated eosinophils flickering mPT mediated activation of JNK [68].  
3. Reactive Oxygen Species (ROS) and Pro-Apoptotic Signalling Pathways  
Reactive oxygen species such as superoxide O2
•− and hydrogen peroxide H2O2 were demonstrated 
to mediate induced eosinophil apoptosis as well as spontaneous eosinophil apoptosis [52,68,78–81]. In 
most tissues, the mitochondrial electron transport chain and especially the complexes I and III serve as 
the primary source of superoxide (O2
•−) even thought O2
•− can also be generated by function of 
NADPH oxidase or xanthine oxidase in certain immune cells such as eosinophils, neutrophils and 
macrophages following their activation [82]. Approximately five- to ten-fold higher steady state 
concentrations of O2
•− exist in the mitochondrial matrix when compared to the cytosol, according to 
one estimation [83]. Mitochondria have a diverse antioxidant defence system including superoxide 
dismutases (SODs such as Manganese (Mn)-containing SOD), glutathione, glutathione peroxidase, 
catalase, peroxiredoxins etc. In the presence of superoxide dismutase (SOD), O2
•− is converted into a 
more stable non-radical oxidant, hydrogen peroxide (H2O2) that may also function as a signalling 
molecule [84]. Catalase functions by decomposing H2O2 to oxygen and water.  
3.1. ROS  
H2O2 has been shown to induce eosinophil apoptosis and catalase has been demonstrated to 
decrease spontaneous eosinophil apoptosis [55,85]. Eosinophil apoptosis induced by  
excretory-secretory products from helminth was associated with increased levels of H2O2 but not 
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superoxide and reversed by catalase but not by mimetic of superoxide dismutase (SOD). Increased 
H2O2 preceded mitochondrial injury [86]. It is possible that H2O2 often acts as the actual mediator  
of eosinophil apoptosis instead of O2
•−. H2O2-induced apoptosis also required products of the 
mitochondrial respiratory chain because inhibition of mitochondrial respiration by rotenone decreased 
H2O2-induced eosinophil apoptosis [55]. In thymocytes, glucocorticoids induced production of H2O2 
and overexpression of catalase in these cells resulted in their resistance to glucocorticoid-induced 
apoptosis supporting a mediator role of H2O2 in the process [87,88]. In eosinophils, evidence exists 
also for the important role of superoxide itself as the mediator of apoptosis. Glucocorticoids increased 
levels of superoxide in eosinophils after 24 h of treatment [52]. Spontaneous apoptosis as well as 
glucocorticoid-induced apoptosis were associated with decreased level of the mitochondrial 
antioxidant MnSOD but not that of the cytosolic antioxidant CuZnSOD at 24 h [52]. Decreased level 
of MnSOD would lead to increased levels of superoxide radical and decreased formation of H2O2. 
Also, nitric oxide-induced eosinophil apoptosis was reduced by a SOD mimetic, suggesting that 
superoxide is an important mediator [68]. Why are the levels of ROS elevated when eosinophils are on 
their way towards apoptosis? Generally, it is thought that most often increased levels of ROS result 
from compromised antioxidant capacity rather than increased production of superoxide [82,89]. 
Indeed, as discussed above, glucocorticoids were shown to decrease levels of MnSOD in  
eosinophils [52]. The mechanism of glucocorticoid-induced enhancement of ROS has also been 
studied in many cell types other than eosinophils. In thymocytes, glucocorticoid-induced production of 
H2O2 was dependent on complex III of the mitochondrial respiratory chain and these events mediated 
glucocorticoid-induced apoptosis. In isolated mitochondria, glucocorticoids have also been shown to 
inhibit members of the mitochondrial respiratory chain [90,91]. In neural stem cells, treatment with 
dexamethasone resulted in down-regulation of 72% of the investigated genes involved in the 
mitochondrial respiratory chain, as well as 29% of the genes encoding for antioxidant enzymes [92]. 
Altogether, the source of ROS production may vary depending on the pro-apoptotic stimulant. 
Glucocorticoids may elevate ROS by directly modulating function of the enzymes in the mitochondrial 
electron transport chain as well as by transcriptional regulation of antioxidant or respiratory  
chain enzymes.  
ROS are significant mediators of eosinophil apoptosis induced by many pro-apoptotic agents but 
how do they actually mediate eosinophil cell death? At some point, excessive mitochondrial ROS may 
reach a threshold that leads to mPT pore opening resulting in ROS release to the cytosol [76]. In the 
cytosol, ROS may activate several protein kinases as discussed below. According to the hypothesis  
of Zorov et al. the released ROS might trigger a similar phenomenon in neighbouring mitochondria 
and lead to amplified oxidative stress signals, mitochondrial injury and possibly cell death [76]. 
Alternatively, a mPT-independent mechanism was demonstrated where ROS was required for 
mitochondrial membrane permeabilization and cytochrome c release induced by Bid [70]. 
3.2. Kinases Activated by ROS 
Mitogen-activated protein kinases (MAPKs) are serine/threonine kinases mainly activated by 
bacterial products, proinflammatory cytokines, growth factors and environmental stress. MAPK family 
consists of c-jun N-terminal kinase (JNK) 1–3, extracellular regulated kinase (ERK) 1/2, 3, 5 and 7, 
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and p38 kinases. A phosphorylation cascade conducted by MAPK kinase kinases (MAP3K) and 
MAPK kinases (MAP2K) leads to activation of MAPK. MAPKs phosphorylate transcription factors 
resulting in transcription of genes involved in apoptosis, survival, proliferation and differentiation. 
Additionally, MAPKs affect the function of numerous other proteins via phosphorylation. MAPKs are 
inactivated by phosphoprotein phosphatases (MAPK phosphatases (MKPs)) [93–95]. Germinal center 
kinases (GSK) such as mammalian sterile 20-like kinase (Mst) 1 are also activators of MAPK 
pathways and at least some family members function by acting as MAPK kinase kinase kinases 
(MAP4K) [96].  
3.2.1. JNK 
ROS are known activators of MAPKs JNK, p38 and ERK 1/2, known to regulate cell survival and 
death pathways [97]. Of these MAPKs, JNK has been shown to mediate glucocorticoid-induced 
eosinophil apoptosis as well as spontaneous apoptosis, apoptosis induced by nitric oxide and several 
drugs [27,52,68,98–101]. Activation of JNK by ROS seems to be indirect. Even though not shown in 
eosinophils, the actual targets of oxidants such as MAP3K (MEKK1) and apoptosis signal-regulating 
kinase 1 (ASK1 or MAP3K5) reside upstream of JNK, and lead to JNK activation via function of 
MAP2K [97]. In addition, peroxynitrite led to activation of JNK in eosinophils but was found to 
require Fas. Fas was demonstrated to be a direct oxidation target of reactive nitrogen species (RNS) 
but the mechanism of JNK activation via Fas remains unclear [102].  
Kinetics of JNK activation seems to be an important determinant in whether the activation leads to 
survival or apoptosis. Early JNK activation has been described to represent a stress response resulting 
in cell survival signalling while delayed and sustained JNK activation has been typically related to 
apoptosis [97,103,104]. Indeed, early and strong JNK activation was demonstrated as a feature 
preceding glucocorticoid-induced eosinophil apoptosis, as well as apoptosis induced by several other 
factors in eosinophils [52,68,101]. Eosinophil apoptosis induced by glucocorticoids and nitric oxide 
exhibit many similarities such as early and late JNK activation, mPT and caspase activation [52,68]. 
Early JNK activation induced by nitric oxide, was however, not critical for NO-induced apoptosis and 
might initiate a stress response aiming to cell survival [68]. In the study of Gardai et al., early JNK 
phosphorylation stimulated by glucocorticoids was prevented by antioxidant treatment suggesting 
involvement of ROS [52]. Furthermore, in NO-treated eosinophils, early JNK activation was 
dependent on partial mitochondrial permeability transition (mPT) [68]. By combining these results 
with findings of Zorov et al. it can be suggested that early JNK activation in response to 
glucocorticoids could be mediated by mPT stimulated by ROS and the following release of ROS to the 
cytosol [76]. Activation of JunD by JNK might provide a link to cell survival [105].  
Instead, an additional later and sustained activation phase of JNK seems to take place in eosinophils 
undergoing glucocorticoid- and NO-induced apoptosis [52,68] and evidence exists that the late phase 
mediates apoptosis [68,103,104]. Interestingly, it was shown, that ROS oxidizes the inactivators of 
MAPKs, MAP kinase phosphatases (MKPs), thereby inhibiting their action and enabling prolonged 
JNK activation [106]. It is possible that only high levels of ROS lead to oxidation and inactivation of 
MKPs and prolonged JNK activation while low levels of ROS may not influence MKP activity 
resulting in rapid JNK inactivation (Figure 1). This could explain the kinetics of JNK activation in 
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eosinophils. In eosinophils, JNK may be mainly involved in regulating DNA fragmentation, because 
its inhibition prevented DNA fragmentation but not e.g., phosphatidylserine exposure or morphological 
signs in induced apoptosis [99,101].  
3.2.2. ERK  
There remains some controversy whether ERK has a role in mediating cytokine-afforded eosinophil 
survival [57,107,108]. However, evidence exists for its role in mediating eosinophil cell death even 
though it was not involved in eosinophil apoptosis induced by dexamethasone [109]. Activation of 
ERK1/2 (but not ERK5) preceded H2O2-induced caspase activation and eosinophil apoptosis [55]. 
Additionally, Siglec-8 induced ROS-dependent cell death in IL-5-treated eosinophils that was 
mediated by enhanced activation of ERK1/2 [81]. However, siglec-8-induced cell death tended to be 
more necrotic than apoptotic. Recently, paired immunoglobulin-like receptor A (PIR-A) was 
demonstrated to drive eosinophils into apoptosis in the absence of its suppressor PIR-B. The  
pro-apoptotic activity of PIR-A was found to involve Grb2 association and ERK1/2  
phosphorylation [110]. Furthermore, anti-CD30 antibody induced eosinophil apoptosis that was 
partially prevented by inhibitors of MAP/extracellular signal-regulated kinase kinase (MEK) 1 and 
MEK1/2 that lie upstream of ERK1/2 [111].  
3.2.3. p38 
In eosinophils, MAPK p38 has been mainly shown to mediate survival rather than  
apoptosis [108,112,113]. However, eosinophil apoptosis induced by anti-CD30 antibody was partially 
prevented by SB203580, an inhibitor of p38 [111], suggesting that similarly to JNK and ERK, p38 
may also act as mediator of apoptosis in certain circumstances. Whether ROS were involved in the 
activation of p38, remains to be determined.  
3.2.4. Mst 1/2  
Mammalian sterile 20-like kinase (Mst) 1 belonging to the group of germinal center kinases 
(GSKs), is involved in many functions of immune cells including apoptosis [96]. Release of 36 kDa 
fragment of Mst1 correlated with eosinophil apoptosis and was inhibited by catalase and inhibitor of 
caspases [114], suggesting that Mst1 activation was dependent on H2O2 and caspases. In embryonic 
stem cells, Mst1 was demonstrated to be involved in activation of JNK and chromatin condensation 
during apoptosis. This effect was dependent on upstream activators of JNK, MAP2K4 and MAP2K7, 
because when these kinases were suppressed, Mst1 was not able to mediate chromatin  
condensation [115].  
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Figure 1. Hypothetical model to describe the mechanisms and outcomes of MAPK 
activation induced by different levels of ROS. If a pro-apoptotic stimulant induces release 
of ROS that is high enough to quench MKP, this may lead to prolonged JNK activation and 
apoptosis (B); Low levels of ROS may lead to transient activation of JNK due to presence 
of active MKP and end up in a protective response (A). The specific pathway mediating 
activation of Mst1 is unclear. ROS, reactive oxygen species; MAP3K, mitogen-activated 
protein kinase kinase kinase; MAP2K, mitogen-activated protein kinase kinase; JNK, c-Jun 
N-terminal kinase; MKP, MAP kinase phosphatase; Mst1, mammalian sterile 20-like 
kinase 1.  
 
4. Summary and Conclusions  
Mitochondria are extremely central in mediating induced eosinophil apoptosis and are involved in 
many steps from the early stress response to the decision of the cell to cope or undergo apoptosis as 
well as to the final loss of mitochondrial membrane potential. Many clinically relevant inducers of 
eosinophil apoptosis utilize the intrinsic pathway of apoptosis and even the extrinsic pathway 
stimulated by Fas activation involves a critical mitochondrial loop. Glucocorticoids and nitric oxide 
stimulate an intrinsic pathway with many similar features involving ROS, early and late JNK 
activation and mPT (Figure 2). Additionally, glucocorticoids accelerate degradation of anti-apoptotic 
Mcl-1 which might enable oligomerization and pore-forming activity of Bax. Processing of  
pro-apoptotic Bid into its truncated, pore-forming fragment is also enhanced by glucocorticoids. 
Studies support that ROS may have a central role in mediating many of these events: JNK activation, 
mPT induction and Bid-mediated cytochrome c release. Glucocorticoids decrease levels of 
mitochondrial antioxidants in eosinophils, which most likely enhance their pro-apoptotic effect. 
Understanding of these pathways in eosinophil apoptosis is critical to support development of new 
agents to treat eosinophilic disorders such as asthma. Furthermore, these pathways may also occur in 
other immune cells in response to glucocorticoids, and increase our understanding of the mechanisms 
behind the divergent effects of glucocorticoids on the longevity of different cell types.  
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Figure 2. A proposed model of the pro-apoptotic mechanism of glucocorticoids in 
eosinophils. Glucocorticoid-induced eosinophil apoptosis is partially dependent on 
glucocorticoid receptor and stimulate an intrinsic pathway of apoptosis. Transcriptional 
effects may lead to reduced level of mitochondrial antioxidant MnSOD and elevated ROS. 
It is also possible that glucocorticoids directly inhibit mitochondrial respiratory chain 
enzymes. Elevated ROS may lead to mPT and release of ROS to the cytosol. ROS inhibits 
MKP and stimulates activation of the MAPK pathway. Glucocorticoids may also enhance 
degradation of anti-apoptotic Mcl-1L by a transcriptional route. Degradation of Mcl-1L 
enables oligomerization and pore-forming activity of Bax leading to mitochondrial outer 
membrane permeabilization. Processing of pro-apoptotic Bid into its truncated, pore-forming 
fragment is also enhanced by glucocorticoids. Abbreviations: GR, glucocorticoid receptor; 
Mcl-1L, myeloid cell leukemia 1 (long); MnSOD, manganese superoxide dismutase; mPT, 
mitochondrial permeability transition; CytC, cytochrome c; MKP, map kinase phosphatase; 
JNK, c-Jun N-terminal kinase; MAP3K, mitogen-activated protein kinase kinase kinase; 
MAP2K, mitogen-activated protein kinase kinase. 
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